Effect of ribociclib Plus fulvestrant on overall survival in the treatment of advanced breast cancer - updated MONALEESA-3 results

被引：0
|
作者：
Dubianski, Roman [1 ]
机构：
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Breast Canc & Reconstruct Surg, WK Roentgena 5 St, PL-02781 Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2022年 / 18卷 / 03期
关键词：
breast cancer; ribociclib; fulvestrant; CDK4/6; inhibitor; PHASE-I; TRIAL; THERAPY;
D O I：
10.5603/OCP.2021.0034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The results of the treatment of ER-positive/HER2-negative advanced breast cancer have been improved in the last few years due to the use of CDK4/6 inhibitors combined with endocrine therapy. Ribociclib with fulvestrant significantly prolonged progression-free survival and overall survival in the phase-III MONALEESA-3 trial. The newest update of the trial (after 56.3 months of observation) showed significant improvement in overall survival in the experimental arm for more than ayear: mOS was 53.7 months in the ribociclib plus fulvestrant arm and 41.5 months in the placebo plus fulvestrant arm (risk reduction of 27%). Subgroup analysis confirmed the efficacy of the treatment in both the first and second lines of treatment. The study also showed that adding ribociclib to the endocrine treatment prolongs the median time to chemotherapy. No new toxicities were observed in longer observation.
引用
收藏
页码：189 / 194
页数：6
相关论文
共 50 条
  • [1] Commentary to Effect of ribociclib plus fulvestrant on overall survival in the treatment of advanced breast cancer - updated MONALEESA-3 results
    Radecka, Barbara
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (03): : 195 - 196
  • [2] Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen
    Fasching, Peter A.
    De Laurentiis, Michelino
    Im, Seock-Ah
    Petrakova, Katarina
    Bianchi, Giulia V.
    Esteva, Francisco J.
    Martin, Miguel
    Nusch, Arnd
    Sonke, Gabe S.
    De la Cruz-Merino, Luis
    Beck, J. Thaddeus
    Pivot, Xavier
    Sondhi, Manu
    Wang, Yingbo
    Chakravartty, Arunava
    Rodriguez-Lorenc, Karen
    Taran, Tetiana
    Jerusalem, Guy
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (06): : 514 - 524
  • [3] Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
    P. Neven
    P. A. Fasching
    S. Chia
    G. Jerusalem
    M. De Laurentiis
    S.-A. Im
    K. Petrakova
    G. V. Bianchi
    M. Martín
    A. Nusch
    G. S. Sonke
    L. De la Cruz-Merino
    J. T. Beck
    J. P. Zarate
    Y. Wang
    A. Chakravartty
    C. Wang
    D. J. Slamon
    Breast Cancer Research, 25
  • [4] Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant
    Neven, P.
    Fasching, P. A.
    Chia, S.
    Jerusalem, G.
    De Laurentiis, M.
    Im, S. -a.
    Petrakova, K.
    Bianchi, G. V.
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    de la Cruz-merino, L.
    Beck, J. T.
    Zarate, J. P.
    Wang, Y.
    Chakravartty, A.
    Wang, C.
    Slamon, D. J.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [5] Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3
    Fasching, P. A.
    Esteva, F. J.
    Pivot, X.
    Nusch, A.
    Beck, J. T.
    Chan, A.
    Pieris-Gunatilaka, A.
    Wang, Y.
    Lanoue, B.
    Chandiwana, D.
    Neven, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2-Advanced Breast Cancer in the MONALEESA-3 Trial
    Jerusalem, Guy
    Delea, Thomas E.
    Martin, Migule
    De Laurentiis, Michelino
    Nusch, Arnd
    Beck, J. Thaddeus
    Chan, Arlene
    Im, Seock-Ah
    Neven, Patrick
    Lonshteyn, Alexander
    Chandiwana, David
    Lanoue, Brad
    Fasching, Peter A.
    CLINICAL BREAST CANCER, 2022, 22 (04) : 326 - 335
  • [7] Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
    Fasching, Peter A.
    Beck, J. Thaddeus
    Chan, Arlene
    De Laurentiis, Michele
    Esteva, Francisco J.
    Jerusalem, Guy
    Neven, Patrick
    Pivot, Xavier
    Bianchi, Giulia V.
    Martin, Miguel
    Chandiwana, David
    Lanoue, Brad
    Ridol, Antonia
    Wang, Yingbo
    Lorenc, Karen Rodriguez
    Nusch, Arnd
    BREAST, 2020, 54 : 148 - 154
  • [8] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen K. L.
    Jerusalem, Guy Heinrich Maria
    De laurentiis, Michelino
    Im, Seock-Ah
    Petrakova, Katarina
    Bianchi, Giulia Valeria
    Martin, Miguel
    Nusch, Arnd
    Sonke, Gabe S.
    de la Cruz-Merino, Luis
    Beck, J. Thaddeus
    Wang, Craig
    Deore, Uday
    Chakravartty, Arunava
    Zarate, Juan Pablo
    Taran, Tetiana
    Fasching, Peter A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Jerusalem, G.
    De Laurentiis, M.
    Im, S.
    Petrakova, K.
    Bianchi, G. Valeria
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Ji, Y.
    Wang, C.
    Deore, U.
    Chakravartty, A.
    Zarate, J. P.
    Taran, T.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 1015 - 1024
  • [10] Ribociclib plus Fulvestrant in Advanced Breast Cancer
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23):
12345